Last reviewed · How we verify

Aripiprazole; Quetiapine — Competitive Intelligence Brief

Aripiprazole; Quetiapine (Aripiprazole; Quetiapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic combination. Area: Psychiatry/Neurology.

marketed Atypical antipsychotic combination Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole; Quetiapine (Aripiprazole; Quetiapine) — Taichung Veterans General Hospital. This is a combination of two atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aripiprazole; Quetiapine TARGET Aripiprazole; Quetiapine Taichung Veterans General Hospital marketed Atypical antipsychotic combination Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Intramuscular aripiprazole, olanzapine Intramuscular aripiprazole, olanzapine Veterans Medical Research Foundation marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Methylphenidate, aripiprazole, and combination Methylphenidate, aripiprazole, and combination Tri-Service General Hospital marketed Stimulant and atypical antipsychotic combination Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor
Lithium carbonate + perospirone hydrochloride Lithium carbonate + perospirone hydrochloride Shanghai Mental Health Center marketed Mood stabilizer + atypical antipsychotic combination Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
venlafaxine XR plus aripiprazole venlafaxine XR plus aripiprazole University of Pittsburgh marketed SNRI plus atypical antipsychotic combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor
Lamotrigine + Aripiprazole Lamotrigine + Aripiprazole Otsuka Pharmaceutical Development & Commercialization, Inc. marketed Anticonvulsant/mood stabilizer + atypical antipsychotic combination Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole)
Sertraline + Olanzapine Sertraline + Olanzapine Weill Medical College of Cornell University marketed SSRI + atypical antipsychotic combination Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic combination class)

  1. Changhua Christian Hospital · 1 drug in this class
  2. Heinrich-Heine University, Duesseldorf · 1 drug in this class
  3. Taichung Veterans General Hospital · 1 drug in this class
  4. Xian-Janssen Pharmaceutical Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole; Quetiapine — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-quetiapine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: